Comparison of the cost to reach A1C targets in patients with type-2 diabetes mellitus on oral antidiabetic agents and either biphasic insulin aspart 70/30 or insulin glargine

被引：0
|
作者：
Cobden, D
Allen, E
Botteman, M
机构：
[1] PharMerit, Bethesda, MD USA
[2] Novo Nordisk Inc, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)62953-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：358 / 358
页数：1
相关论文
共 50 条
  • [21] COST-UTILITY OF BIPHASIC INSULIN ASPART COMPARED WITH PREMIXED HUMAN INSULIN IN TREATMENT OF TYPE-2 DIABETES MELLITUS IN POLAND
    Szmurlo, D.
    Gurda-Duda, A.
    Rys, P.
    Rutkowski, J.
    Skrzekowska-Baran, I
    Plisko, R.
    Wladysiuk, M.
    VALUE IN HEALTH, 2009, 12 (07) : A409 - A409
  • [22] An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes
    Gupta, Vishal
    Baabbad, Ranya
    Hammerby, Eva
    Nikolajsen, Annie
    Shafie, Asrul Akmal
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (04) : 263 - 272
  • [23] Effect of biphasic insulin aspart 30/70 (BIAsp30) in combination with metformin on glycaemic control in subjects with type 2 diabetes not optimally controlled on oral antidiabetic agents
    Naiker, P.
    Makan, H. A.
    Omar, M. A. K.
    Kedijang, T.
    Kong, L. L. L.
    DIABETOLOGIA, 2006, 49 : 599 - 600
  • [24] Comparison of biphasic insulin aspart and human insulin premix in patients with Type 2 diabetes
    Itoh, Hiroshi
    Morikawa, Akizuki
    Asai, Mahito
    Nishimura, Hideo
    Atoh, Keita
    Mutou, Eiji
    Oshima, Eiji
    Iwashima, Yasunor-I
    Miura, Takanori
    Sekiguchi, Masatomo
    Tani, Mitsunori
    Haneda, Masakazu
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 79 : S65 - S65
  • [25] Biphasic insulin aspart 30 and insulin glargine administered with oral anti-diabetic drugs in type 2 diabetes mellitus: a systematic review and meta-analysis
    Schubert, A.
    Ziola, M.
    Siejka, S.
    Rys, P.
    Skrzekowska-Baran, I.
    Malecki, M. T.
    DIABETOLOGIA, 2011, 54 : S420 - S420
  • [26] Treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naive type 2 diabetes patients: long-term effects on diabetesrelated complications
    Lammert, M
    Palmer, AJ
    Roze, S
    Valentine, WJ
    DIABETOLOGIA, 2005, 48 : A308 - A309
  • [27] Over 75% of patients with type 2 diabetes reached target A1C by adding biphasic insulin aspart 70/30 to optimized metformin and pioglitazone treatment
    Raskin, Philip
    Braceras, Rogelio
    Schwartz, Sherwyn
    Chaykin, Louis
    Chu, Pei-Ling
    Wynne, Alan
    DIABETES, 2006, 55 : A131 - A131
  • [28] The comparison of different injection times of biphasic insulin aspart 30 in the treatment of type 2 diabetes mellitus in elderly patients
    石慧敏
    ChinaMedicalAbstracts(InternalMedicine), 2017, 34 (03) : 152 - 152
  • [29] Clopidogrel resistance in patients with type 2 Diabetes Mellitus: A comparison between oral antidiabetic agents and insulin
    Ariturk, Zuhal
    Cil, Habib
    Gunduz, Ercan
    Yavuz, Celal
    Kaya, Hasan
    Ertas, Faruk
    Oylumlu, Mustafa
    Soydinc, Serdar
    HEALTHMED, 2012, 6 (10): : 3323 - 3328
  • [30] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART (IDEGASP) COMPARED WITH BIPHASIC INSULIN ASPART (BIASP 30) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A MEXICAN HEALTHCARE PERSPECTIVE
    Sanchez-Pedraza, V
    Hansen, B. B.
    Gundgaard, J.
    Uranga Romano, Garca J.
    Evans, M.
    VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
12345